Safety and efficacy of Corifollitropin Alfa N02 for older women undergoing IVF/ICSI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multi-centre, single-arm observational study conducted at a major hospital in Beijing. It assesses safety and efficacy of Corifollitropin alfa N02 during controlled ovarian stimulation for elderly Chinese women seeking ART. The study also explores how well participants adhere to treatment and their satisfaction with the COS process. Inclusion requires normal ovarian reserve and a fixed antagonist COS protocol with Corifollitropin alfa N02, while several historical eligibility exclusions aim to minimize OHSS risk and prior poor response. Outcomes focus on safety signals and preliminary efficacy in this specific age group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Able to communicate well with investigators, understand and comply with trial requirements, participate voluntarily, and provide signed informed consent after full understanding.
2. Married women aged 36 to 40 years (exclusive of boundary values).
3. Normal ovarian function: AMH ≥ 1.1 μg/L and basal FSH \< 10 IU/L.
4. Scheduled to undergo controlled ovarian stimulation (COS) and IVF/ICSI using a fixed antagonist protocol combined with Corifollitropin alpha N02 injection.

Exclusion Criteria:

1. ≥3 previous cycles of controlled ovarian stimulation (COS)
2. Recurrent pregnancy loss: ≥3 previous pregnancy losses (including spontaneous abortion, biochemical pregnancy, and missed abortion).
3. Repeated implantation failure: ≥3 embryo transfer cycles (fresh or frozen) or failure to achieve clinical pregnancy after transfer of ≥4 high-quality embryos in total.
4. High risk of ovarian hyperstimulation syndrome (OHSS), defined by any of the following:

   * Diagnosed with polycystic ovary syndrome (PCOS);

     * Total number of AFC in both ovaries \>20 on Day 2-3 of menstruation; ③ Previous cycle cancellation (including canceled embryo transfer) due to high ovarian response or high OHSS risk; ④ History of OHSS; ⑤ Other conditions judged by the investigator to confer high OHSS risk after comprehensive evaluation.
5. Poor ovarian function, defined by any of the following:

   ① Previous poor ovarian response (≤3 oocytes retrieved following conventional full-dose gonadotropin stimulation);

   ② Total AFC in both ovaries \<5.
6. Presence of any reproductive, endocrine, or immune disorders that may affect pregnancy, as assessed by the investigator.
7. Abnormal uterine bleeding.
8. Presence of systemic diseases (e.g., cardiovascular, digestive, neurological, hematological disorders) deemed unsuitable for study participation by the investigator, or severe diseases incompatible with pregnancy.
9. Hypersensitivity or history of allergy to active ingredients or excipients of gonadotropins (Gn), GnRH antagonists, or progesterone preparations, or with documented contraindications to these medications.
10. History of alcoholism, heavy smoking, drug addiction, or substance abuse.
11. Scheduled to undergo preimplantation genetic testing (PGT).
12. Currently participating in another clinical trials and receiving investigational products.
13. Any other conditions deemed by the investigator to render the subject unsuitable for trial participation based on safety considerations.

Where it's running

• Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Mengsheng Zhang
• Email: zhangmengsheng@genscigroup.com
• Phone: +86 18190952182

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted embryo selection on day 5 in IVF for infertility

  This trial tests whether an AI-based embryo selection tool can help pick the best embryo for transfer on day 5 in IVF/ICSI to improve pregnancy chances for people with infertility.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07844083

• Preserving sperm quality with aging through cryopreservation

  This study tests whether freezing and thawing sperm can help keep younger-like DNA and molecular traits in men as they age.

  Recruiting IVI Murcia · Murcia, Murcia · NCT07814235

• Unstimulated Egg Retrieval with CAPA-IVM and Euploid Embryo Transfer

  This study tests whether eggs can be collected without ovarian stimulation, matured in the lab, and used to create a single euploid embryo for transfer in infertility patients.

  Recruiting CARE Fertility Texas · Bedford, Texas · NCT07801105

• Ultra-Long GnRH-a Pretreatment Before Frozen Embryo Transfer for Deep Infiltrating Endometriosis

  In people under 40 with deep infiltrating endometriosis and infertility, the study tests whether two injections of a GnRH agonist before hormone support improve pregnancy outcomes in their first frozen-thawed embryo transfer.

  Recruiting Phase 4 Nanjing University · Nanjing, Jiangsu · NCT07696351

• Endometrial Waves and Pregnancy in FET Cycles with Hormone Therapy

  This study tests whether patterns of uterine contractions during hormone-prepared frozen embryo transfer affect pregnancy outcomes.

  Recruiting Mỹ Đức Hospital · Ho Chi Minh City · NCT07675213

• Environmental and lifestyle factors linked to ART success in infertility patients

  This study follows 5,000 infertile men and women to see how environmental exposures and lifestyle relate to the success of assisted reproductive technology.

  Recruiting The Third Xiangya Hospital of Central South University · Changsha, Hunan · NCT07641387

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.